0.00Open0.03Pre Close0 Volume328 Open Interest17.50Strike Price0.00Turnover0.00%IV20.23%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-6DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma486.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
No comment yet